» Articles » PMID: 38927061

Molecular Mechanisms of the Impaired Heparin Pentasaccharide Interactions in 10 Antithrombin Heparin Binding Site Mutants Revealed by Enhanced Sampling Molecular Dynamics

Overview
Journal Biomolecules
Publisher MDPI
Date 2024 Jun 27
PMID 38927061
Authors
Affiliations
Soon will be listed here.
Abstract

Antithrombin (AT) is a critical regulator of the coagulation cascade by inhibiting multiple coagulation factors including thrombin and FXa. Binding of heparinoids to this serpin enhances the inhibition considerably. Mutations located in the heparin binding site of AT result in thrombophilia in affected individuals. Our aim was to study 10 antithrombin mutations known to affect their heparin binding in a heparin pentasaccharide bound state using two molecular dynamics (MD) based methods providing enhanced sampling, GaMD and LiGaMD2. The latter provides an additional boost to the ligand and the most important binding site residues. From our GaMD simulations we were able to identify four variants (three affecting amino acid Arg47 and one affecting Lys114) that have a particularly large effect on binding. The additional acceleration provided by LiGaMD2 allowed us to study the consequences of several other mutants including those affecting Arg13 and Arg129. We were able to identify several conformational types by cluster analysis. Analysis of the simulation trajectories revealed the causes of the impaired pentasaccharide binding including pentasaccharide subunit conformational changes and altered allosteric pathways in the AT protein. Our results provide insights into the effects of AT mutations interfering with heparin binding at an atomic level and can facilitate the design or interpretation of in vitro experiments.

Citing Articles

Identification of two point mutations associated with inherited antithrombin deficiency.

Lai S, Chang C, Lee H, Chen Y Thromb J. 2024; 22(1):107.

PMID: 39627773 PMC: 11613604. DOI: 10.1186/s12959-024-00677-6.

References
1.
CASO R, Lane D, Thompson E, Zangouras D, Panico M, Morris H . Antithrombin Padua. I: Impaired heparin binding caused by an Arg47 to his (CGT to CAT) substitution. Thromb Res. 1990; 58(2):185-90. DOI: 10.1016/0049-3848(90)90175-c. View

2.
Gettins P, Olson S . Activation of antithrombin as a factor IXa and Xa inhibitor involves mitigation of repression rather than positive enhancement. FEBS Lett. 2009; 583(21):3397-400. PMC: 3821923. DOI: 10.1016/j.febslet.2009.10.005. View

3.
Gindele R, Selmeczi A, Olah Z, Ilonczai P, Pfliegler G, Marjan E . Clinical and laboratory characteristics of antithrombin deficiencies: A large cohort study from a single diagnostic center. Thromb Res. 2017; 160:119-128. DOI: 10.1016/j.thromres.2017.10.023. View

4.
Miao Y, Feher V, McCammon J . Gaussian Accelerated Molecular Dynamics: Unconstrained Enhanced Sampling and Free Energy Calculation. J Chem Theory Comput. 2015; 11(8):3584-3595. PMC: 4535365. DOI: 10.1021/acs.jctc.5b00436. View

5.
Vanquelef E, Simon S, Marquant G, Garcia E, Klimerak G, Delepine J . R.E.D. Server: a web service for deriving RESP and ESP charges and building force field libraries for new molecules and molecular fragments. Nucleic Acids Res. 2011; 39(Web Server issue):W511-7. PMC: 3125739. DOI: 10.1093/nar/gkr288. View